Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer

International Journal of Cancer

Volumn 107, Issue 2, 2003, Pages 177-182

  Rivenzon Segal, Dalia ^a   Boldin Adamsky, Swetlana ^a   Seger, Dalia ^a   Seger, Rony ^a   Degani, Hadassa ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Breast cancer; Estrogen; Glucose; Lactate; Magnetic resonance spectroscopy; Tamoxifen

Indexed keywords

ESTROGEN; GLUCOSE; GLUCOSE TRANSPORTER 1; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CONTROLLED STUDY; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; METABOLIC REGULATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SPECTROSCOPY; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ESTROGENS; FEMALE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; MONOSACCHARIDE TRANSPORT PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0141857820     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11387     Document Type: Article

References (44)

1. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
2. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 2000;57:170-8.
3. Pauwels EK, Sturm EJ, Bombardieri E, Cleton FJ, Stokkel MP. Positron-emission tomography with [18F] fluorodeoxylucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 2000;126:549-59.
4. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-5.
5. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science 1987;235:1495-8.
6. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000;275:21797-800.
7. Neeman M, Degani H. Metabolic studies of estrogen- and tamoxifen-treated human breast cancer cells by nuclear magnetic resonance spectroscopy. Cancer Res 1989;49:589-94.
8. Furman E, Rushkin E, Margalit R, Bendel P, Degani H. Tamoxifen induced changes in MCF7 human breast cancer: in vitro and in vivo studies using nuclear magnetic resonance spectroscopy and imaging. J Steroid Biochem Mol Biol 1992;43:189-95.
9. Rivenzon-Segal D, Rushkin E, Polak-Charcon S, Degani H. Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells. Am J Physiol Endocrinol Metab 2000;279: E508-19.
10. Zamora-Leon SP, Golde DW, Concha II, Rivas CI, Delgado-Lopez F, Baselga J, Nualarts F, Vera JC. Expression of the fructose transporter GLUT5 in human breast cancer. Proc Natl Acad Sci 1996;93:1847-52.
11. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 1999;59:4709-14.
12. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 1995;15:2895-8.
13. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of human erythrocyte glucose transporter GLUT1 in human cancers. Cancer Res 1996;56:1164-7.
14. Zimmerman RL, Goonewardene S, Fogt F. Glucose transporter Glut-1 is of limited value for detecting breast carcinoma in serous effusions. Mod Pathol 2001;14:748-51.
15. Alo PL, Visca P, Botti C, Galati GM, Sebastiani V, Andreano T, Di Tondo U, Pizer ES. Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am J Clin Pathol 2001;116:129-34.
16. Grover-Mckay M, Walsh SA, Seftor EA, Thomas PA, Hendrix MJC. Role of glucose transporter 1 protein in human breast cancer. Phatol. Oncol. Res. 1998;4:115-120
17. Kang SS, Chun YK, Hur MH, Lee HK, Kim YJ, Hong SR, Lee JH, Lee SG, Park YK. Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Can Res 2002;93:1123-8.
18. Lippman ME, Bolan G, Huff K. Human breast cancer responsive to androgen in long term tissue culture. Nature 1975;258:339-41.
19. Wilding G, Lippman ME, Dickson RB. The cellular response of human breast cancer to estrogen. Prog Clin Biol Res 1988;262:181-96.
20. Radmacher MD, Simon R. Estimation of tamoxifen's efficiency for preventing the formation and growth of breast cancer. J Natl Cancer Inst 2000;92:48-53.
21. Jensen EV, DeSombre ER. Estrogen-receptor interaction. Science 1973;182:126-34.
22. Ferguson AT, Davidson NE. Regulation of estrogen receptor alpha function in breast cancer. Crit Rev Oncog 1997;8:29-46.
23. Muss HB. Role of adjuvant endocrine therapy in early-stage breast cancer. Semin Oncol 2001;28:313-21.
24. Smith DE, Gorski J. Estrogen control of uterine glucose metabolism. An analysis based on the transport and phosphorylation of 2-deoxy-glucose. J Biol Chem 1968;243:4169-74.
25. 13C NMR kinetic studies of the rapid stimulation of glucose metabolism by estrogen in immature rat uterus. NMR Biomed 1994;7:209-17.
26. Welch RD, Gorski J. Regulation of glucose transporters by estradiol in the immature rat uterus. Endocrinology 1999;140:3602-8.
27. Cheng CM, Cohen M, Wang J, Bondy CA. Estrogen augments glucose transporter and IGF1 expression in primate cerebral cortex. FASEB J 2001;15:907-15.
28. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 2001;93:1449-57.
29. Furman-Haran E, Mareztek AF, Goldberg I, Horowitz A, Degani H. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 1994;34:5511-4.
30. 13C MRS. Am J Physiol Endocrinol Metab 2002;283:E623-30.
31. Zhang JZ, Behrooz A, Ismail-Beigi F. Regulation of glucose transport by hypoxia. Am J Kidney Dis 1999;34:189-202.
32. Ci L, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003;21:28-34.
33. Muramatsu M, Inoue S. Estrogen receptors: how do they control reproductive and nonreproductive functions? Biochem Biophys Res Commun 2000;270:1-10.
34. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
35. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 2002;41:79-83.
36. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7.
37. Santos G, Scott GK, Lee WMF, Liu E, Benz C. Estrogen induce post-transcriptional modulation of c-myc proto-oncogene in human breast cancer cells. J Biol Chem 1988;263:9565-8.
38. Dubik D, Shiu RPC. Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 1988;263:12705-8.
39. van-der-Burg B, van Selm-Miltenburg AJP, de Laat SW, van Zoelen EJJ. Direct effects of estrogen on c-fos and c-myc oncogene expression and cellular proliferation in human breast cancer cell. Mol Cell Endocrinol 1989;64:223-8.
40. Leygue E, Gol-Winkler R, Gompel A, Louis-Sylvestre C, Soquet L, Staub S, Kuttenn F, Mauvais-Jarvis P. Estradiol stimulates c-myc proto-oncogene expression in normal human breast epithelial cells in culture. J Steroid Biochem Molec Biol 1995;52:299-305.
41. Venditti M, Iwasiow B, Orr FW, Shiu RPC. C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int J Cancer 2002;99:35-42.
42. Evans SM, Koch CJ, Laughlin KM, Jenkins WT, Van Winkle T, Wilson DF. Tamoxifen induces hypoxia in MCF7 xenografts. Cancer Res 1997;15:5155-61.
43. Maity A, Sall W, Koch CJ, Oprysko PR, Evans SM. Low pO2 and b-estradiol induce VEGF in MCF7 and MCF7-5C cells: relationship to in vivo hypoxia. Breast Cancer Res Treat 2001;67:51-60.
44. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 1999;343:281-99.